4//SEC Filing
Violette Shelia M. 4
Accession 0000950170-25-028245
CIK 0001661998other
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 9:54 PM ET
Size
24.5 KB
Accession
0000950170-25-028245
Insider Transaction Report
Form 4
Q32 Bio Inc.QTTB
Violette Shelia M.
Chief Scientific Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-02-24−56,413→ 0 totalExercise: $16.82Exp: 2034-03-24→ Common Stock (56,413 underlying) - Award
Stock Option (Right to Buy)
2025-02-24+56,413→ 56,413 totalExercise: $2.54Exp: 2034-03-24→ Common Stock (56,413 underlying) - Award
Common Stock
2025-02-24+37,500→ 61,374 total - Award
Stock Option (Right to Buy)
2025-02-24+32,891→ 32,891 totalExercise: $2.54Exp: 2030-12-01→ Common Stock (32,891 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-24−17,506→ 0 totalExercise: $7.50Exp: 2033-04-26→ Common Stock (17,506 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-24−13,305→ 0 totalExercise: $7.29Exp: 2031-03-24→ Common Stock (13,305 underlying) - Award
Stock Option (Right to Buy)
2025-02-24+13,305→ 13,305 totalExercise: $2.54Exp: 2031-03-24→ Common Stock (13,305 underlying) - Award
Stock Option (Right to Buy)
2025-02-24+17,506→ 17,506 totalExercise: $2.54Exp: 2033-04-26→ Common Stock (17,506 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-24−32,891→ 0 totalExercise: $7.29Exp: 2030-12-01→ Common Stock (32,891 underlying)
Holdings
- 36,277(indirect: By LLC)
Common Stock
Footnotes (5)
- [F1]The restricted stock units ("RSUs") vest in four equal installments, 25% shall vest 6 months from February 24, 2025 (the "Grant Date"), 25% shall vest 12 months from the Grant Date, 25% shall vest 24 months from the Grant Date, and 25% shall vest 36 months from Grant Date. Each RSU represents a contingent right to receive one share of Issuer common stock.
- [F2]Shares held by Violette Holdings LLC ("Violette Holdings"). The Reporting Person is a manager of Violette Holdings and disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such shares for purposes of Section 16 of the Exchange Act or for any other purpose.
- [F3]On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F4]This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
- [F5]The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.
Documents
Issuer
Q32 Bio Inc.
CIK 0001661998
Entity typeother
Related Parties
1- filerCIK 0002016144
Filing Metadata
- Form type
- 4
- Filed
- Feb 25, 7:00 PM ET
- Accepted
- Feb 26, 9:54 PM ET
- Size
- 24.5 KB